Mpox (Monkeypox) Virus and Its Co-Infection with HIV, Sexually Transmitted Infections, or Bacterial Superinfections: Double Whammy or a New Prime Culprit?

Benjamin M. Liu,Natella Y. Rakhmanina,Zhilong Yang,Michael I. Bukrinsky

DOI: https://doi.org/10.3390/v16050784

2024-05-16

Viruses

Abstract:Epidemiologic studies have established that mpox (formerly known as monkeypox) outbreaks worldwide in 2022–2023, due to Clade IIb mpox virus (MPXV), disproportionately affected gay, bisexual, and other men who have sex with men. More than 35% and 40% of the mpox cases suffer from co-infection with HIV and sexually transmitted infections (STIs) (e.g., Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, and herpes simplex virus), respectively. Bacterial superinfection can also occur. Co-infection of MPXV and other infectious agents may enhance disease severity, deteriorate outcomes, elongate the recovery process, and potentially contribute to the morbidity and mortality of the ensuing diseases. However, the interplays between MPXV and HIV, bacteria, other STI pathogens and host cells are poorly studied. There are many open questions regarding the impact of co-infections with HIV, STIs, or bacterial superinfections on the diagnosis and treatment of MPXV infections, including clinical and laboratory-confirmed mpox diagnosis, suboptimal treatment effectiveness, and induction of antiviral drug resistance. In this review article, we will discuss the progress and knowledge gaps in MPXV biology, antiviral therapy, pathogenesis of human MPXV and its co-infection with HIV, STIs, or bacterial superinfections, and the impact of the co-infections on the diagnosis and treatment of mpox disease. This review not only sheds light on the MPXV infection and co-infection of other etiologies but also calls for more research on MPXV life cycles and the molecular mechanisms of pathogenesis of co-infection of MPXV and other infectious agents, as well as research and development of a novel multiplex molecular testing panel for the detection of MPXV and other STI co-infections.

virology

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the monkeypox virus (Mpox Virus, MPXV) and its interactions and impacts with HIV, sexually transmitted infections (STIs), or bacterial super - infections co - infections. Specifically:

1. **MPXV Biology**: Explore the biological characteristics of MPXV, including its life cycle, replication mechanism, and interactions with other pathogens. It is mentioned in the paper that many molecular details in the MPXV life cycle are still unclear at present, such as the recognition of cell receptors, the specific mechanisms of virion morphogenesis and release, etc.

2. **Antiviral Treatment**: Discuss the treatment effects of currently available antiviral drugs (such as tecovirimat and brincidofovir) on MPXV, as well as the possible drug - resistance problems of these drugs. The study found that tecovirimat has developed drug - resistance in some HIV patients receiving long - term treatment, while brincidofovir and cidofovir seem less likely to develop drug - resistance due to the high conservation of MPXV DNA polymerase.

3. **Pathology of Human MPXV Infection and Its Co - infections**: Analyze the clinical manifestations and pathological mechanisms of MPXV infection alone and co - infection with HIV, STIs, or bacterial super - infections. Studies have shown that co - infection of MPXV with HIV or other pathogens may exacerbate the condition, prolong the recovery time, and increase the morbidity and mortality of the disease. For example, during the MPXV epidemic in Nigeria from 2017 - 2018, patients co - infected with HIV and MPXV showed a longer clinical course, more lesions, and a higher incidence of bacterial super - infections.

4. **Impacts on Diagnosis and Treatment**: Explore the impacts of co - infections on the diagnosis and treatment of MPXV, including clinical and laboratory - confirmed mpox diagnosis, poor treatment effects, and induction of antiviral drug - resistance. The article points out that co - infections may lead to difficulties in diagnosis and a decline in treatment effects, and new multi - molecular detection methods need to be developed to simultaneously detect MPXV and other pathogens.

5. **Immune Response**: Study the impacts of MPXV infection and its co - infections on the host immune system, especially the roles of innate immune response and adaptive immune response. The article mentions that MPXV can inhibit the activation of specific T cells, evade the responses of antiviral CD4+ and CD8+ T cells, thereby blocking the production of inflammatory cytokines and promoting the spread of the virus.

6. **Vaccines and Trained Immunity**: Discuss the protective effect of smallpox vaccines on MPXV and the concept of "trained immunity", that is, innate immune cells acquire memory after the initial stimulation and can produce enhanced responses to subsequent infections or stimuli. The study found that the population vaccinated with smallpox vaccines has a certain protective effect against HIV - 1 infection, which may be related to trained immunity.

In summary, this paper aims to comprehensively review and analyze the research progress in the biology, pathology, diagnosis, and treatment of MPXV infection and its co - infections, and at the same time points out the directions for future research, including the molecular mechanisms of the MPXV life cycle, drug - resistance monitoring, the development of new diagnostic methods, and the research on trained immunity and heterologous immunity.